Restrictions on releases of polychlorinated dibenzo-dioxins and polychlorinated dibenzofurans (PCDDs/Fs) to the environment from industrial practices have resulted in an attendant decrease in levels of these compounds in the environment. Continued environmental monitoring and biomonitoring of PCDDs/Fs ensure that exposures do not increase unexpectedly or unnoticed. Perhaps the most highly exposed part of the population, however, is the breastfed infant and a periodic assessment of levels of dioxins and furans in human milk provides exposure information for infants. A previous international review of levels of PCDDs/Fs in human milk based on data from the 1970's to the mid-1990's showed a decline in many countries for which data were available. In this paper, recent (1998)(1999)(2000)(2001)(2002)(2003)(2004)(2005) global data on PCDDs/Fs in human milk are described. A comparison of these recent data to pre-1998 data suggests a continuing decline in global levels of PCDDs/Fs in human milk. In addition, this paper explores research on physiological origins of these compounds in human milk (e.g., adipose tissue mobilization, recent dietary exposures). The question of whether the presence of PCDDs/Fs in milk is from the lifetime accumulation of PCDDs/Fs in adipose tissue or current diet (or, as is more likely, a complex combination of both) remains unanswered. Whether diet during lactation has a greater influence on milk levels PCDDs/Fs levels than previously suspected, and whether infant exposures to PCDDs/Fs via breastfeeding could be reduced by changes in diet during lactation, are important F and currently unexplored F lines of inquiry.
Introduction
Dioxins and furans polychlorinated dibenzo-dioxins and polychlorinated dibenzofurans (PCDDs/Fs) are the unwanted byproducts of several industrial (e.g., incineration, pulp bleaching, pesticide production), natural (e.g., forest fires), and individual (e.g., backyard burning of waste) processes. Restrictions on the release of PCDDs/Fs to the environment from industrial practices have resulted in an associated decrease in levels of these compounds in the environment; levels in humans, as measured in blood and milk, have also declined over the last few decades (USEPA, 2004) . Continued environmental monitoring and biomonitoring of PCDDs/Fs serve to ensure that exposures do not increase either unexpectedly or unnoticed. The US Centers for Disease Control and Prevention measures PCDDs/Fs in serum as part of its ongoing NHANES program, and levels continue to decline in the general US population (CDC, 2005) . Perhaps the most highly exposed part of the population, however, is the breastfed infant, where exposures to PCDDs/Fs via ingestion can be higher, on a body weight basis, than during other periods in an person's life (USEPA, 2004) . Thus, a periodic assessment of levels of PCDDs/Fs in human milk provides exposure information for this population. A previous international review of levels of PCDDs/Fs in human milk based on data from the 1970's to the mid-1990's showed a decline in many of those countries for which data were available (LaKind et al., 2001) .
Understanding the source(s) of lipids F and the lipophilic compounds associated with them F in human milk is necessary for estimating future trends for PCDDs/Fs (and other persistent lipophilic compounds) in human milk and for determining whether any proactive measures could be undertaken by expectant and lactating women to reduce levels in their milk. If the majority of PCDDs/Fs derive from the mother's adipose stores from lifetime exposure and accumulation of these compounds, then as levels in humans decline, levels in milk lipids will likely decrease in a similar manner. However, if the principle source of PCDDs/Fs in milk is dietary exposure during lactation, then levels in milk will be less directly linked to lifetime environmental exposures, but rather would be correlated with recent diet (especially diets with high levels of PCDDs/Fs).
In this paper, recent (1998) (1999) (2000) (2001) (2002) (2003) (2004) (2005) global data on PCDDs/ Fs in human milk are described as is the research on the physiological origins of these compounds in human milk (e.g., adipose tissue mobilization, and recent dietary exposures).
Dioxins and Furans F International Levels and Trends in
Human Milk (1998 Milk ( -2005 Although a substantial effort has been devoted to investigations of chemicals of emerging concern in human milk (e.g., polybrominated diphenyl ethers (PDBEs)), reports on PCDDs/Fs in human milk continue to be published, allowing for continued assessment of trends, both temporal and geographic, in levels of these chemicals. This review focuses on published studies of dioxins and furans in human milk during the time period 1998-2005 (Table 1) . As in the prior examination of trends in levels of PCDDs/Fs in human milk (LaKind et al., 2001) , several problematic issues with the data remain, so that a set of guidelines for data inclusion/exclusion as well as data descriptors are necessary.
Guidelines Inconsistent study protocols and small numbers of samples (such that data cannot necessarily be considered representative of a country) can reduce the validity of interstudy comparisons. This issue was examined at the Technical Workshop on Human Milk Surveillance and Research on Environmental Chemicals in the United States (LaKind, 2002) . Despite variations in human milk study design and reporting, the available studies represent the best and only data with which to identify trends and hotspots and therefore are used here to the extent possible. For consistency with the trend information developed for the 1970's-mid-1990's database, uncertainties in the human milk dioxin database are addressed here in the same manner as in the previous assessment as follows (biases introduced by each decision were described in LaKind et al., 2001 ): Date of sampling: For studies that do not provide the actual year that human milk sampling was conducted, the year of publication was used as the sampling date. If the sampling timeframe was 2 years, the earlier reported year was used. For a sampling timeframe of greater than 2 years, the approximate midpoint was chosen. Measure of central tendency: Because human milk PCDD/ F concentrations are not necessarily normally distributed, the median, geometric mean, or other statistic might be the preferred measure of central tendency (Smith, 1999) . In some cases, the central tendency may not be of primary interest; for example, frequencies of extreme (high or low) concentrations might be more important. However, the arithmetic mean was the most commonly reported measure. Data given with other metrics such as medians are included in Table 1 ; only arithmetic means are included in the figures. Levels below limit of detection and missing congener data: Methods for computing toxic equivalents (TEQs) include assigning non-detects a value of zero, or one the halfdetection limit. Where TEQs were calculated by this author, non-reported congeners (i.e., congeners with no data) were assigned a value of zero. Time postpartum: Where longitudinal data are reported, data from samples collected at or near 30 days postpartum (if available) are included in Table 1 .
Trends Along with reductions in releases of PCDDs/Fs to the environment over the last two decades, demonstrated concomitant decreases in human plasma and milk have also been reported. However due to the persistence of PCDDs/Fs in the environment and the long half-life in humans, coupled with the sources of dioxins that either cannot be controlled (e.g., forest fires) or that have not been subject to restrictions (e.g., backyard burning of waste in the US and elsewhere), it is possible that the rate of decline of levels in the environment has decreased or plateaued.
The international data on PCDDs/Fs in human milk were utilized to determine whether any trends in concentrations over the last several years are discernable, and to compare the current levels with those reported for 1970 -1997 (LaKind et al., 2001 . Human milk data were collected for the years 1998-2005 from published sources, including reports published on-line. Data were available from the following countries: Australia, Belgium, Brazil, Bulgaria, Cambodia, China, Croatia, Czech Republic, Egypt, Fiji, Finland, France, Germany, Greece, Hungary, India, Ireland, Japan, Korea, Laos, Luxembourg, Malaysia, New Zealand, Norway, Philippines, Portugal, Rep. Uzbekistan, Slovak Republic, Spain, Sweden, Taiwan, The Netherlands, UK, Ukraine, USA, and Vietnam.
As with the previous assessment (LaKind et al., 2001) , the following information was assembled (not all information was available for each study): Date, country, number of donors/samples, TEQ values, description of sampling location/population, and reference. Unless otherwise noted, total TEQs are given as WHO-TEQs (van den Berg et al., 1998) ( Table 2) .
The results of this data compilation are shown in Figure 1 . Examining these global data in isolation makes an assessment of trends difficult, but a comparison of these data to the pre-1998 data (compiled by LaKind et al., 2001 ) suggests a continuing decline in global levels of PCDDs/Fs in human milk (Figure 2 ). Data in Figure 2 were fitted using LOWESS, a robust locally weighted non-linear regression smoothing method (Cleveland, 1979) . The fitted curve shows a clear downward time trend. The fact that the fitted curve appears different for the two distinct time periods before and after 1994 is likely a byproduct of the fact that much of the data come from two distinct time clusters. Specifically, the number of data points before 1999 and after 2002 is more limited, so the apparent trends outside the 1999-2002 period should be interpreted with care. The negative association between year and TEQ level is supported by the global decline over time in the mean and median levels in milk (mean values for 1999 , 2001 median values for 1999 , 2001 .1, and 7.1 ppt WHO-TEQ lipid basis, respectively). The mean and median values increase after 2002, but the data for this period are less reliable because of the sharp decrease in the number of available studies on which to base the estimates. As the number of published studies covering milk biomonitoring studies from 2003 to 2005 increases, mean and median values for this time period can be assessed with greater certainty.
Recent declines in concentrations of PCDD/F TEQs on a country-specific basis have been reported. For example, in Sweden, a decline in dioxin TEQs in human milk (lipid basis) of 5.9-7.5% per year for primiparous women was reported for the time period 1996-2004, after adjusting for age and pregnancy weight gain (Lignell et al., 2005) . (However, Glynn et al. (2003) did not find a significant decrease in age-adjusted levels of PCDDs/Fs in the milk of women from the Stockholm/Uppsala area of Sweden during the years 1996-2001). In Norway, a 61% decrease in PCDD/F TEQs in human milk was observed over the 15-year time period from 1985 to 2000 (Becher et al., 2002) . Similarly, levels in milk in Australia declined by about 60% from 1993 to 2003 If the published data included TEQ values, these are incorporated in Table 1 . Otherwise, dioxin TEQs were calculated using published concentration data and TEF values from Table 2. a Number of donor refers to the number of women participating in the study. In many cases, the participants' milk was combined, or pooled, to make a fewer number of ''samples.'' So, for example, 10/1 represents 10 women providing milk samples, which were pooled to make one sample for analysis. Recent global trends and sources of dioxins LaKind (Harden et al., 2004) . Between 1988 Between -89 and 2002 Between -2003 in PCDDs/Fs in human milk from 18.9 to 5.7 pg TEQ-WHO/g lipid were found in the Irkutsk Region of Russia (Mamontova et al., 2005a) .
In contrast, Kunisue et al. (2006) reported that levels of PCDDs/Fs in Japanese human milk in 2002 were higher than those collected during 1998-2000, despite national emissions of dioxins decreasing substantially over a similar time period. After 2002, levels of PCDDs/Fs in human milk decreased to 1998 levels.
Sources and Transport of Lipids and PCDDs/Fs to Human Milk
It is widely reported that lipophilic, persistent compounds such as PCDDs/Fs partition in body lipids such that concentrations of these compounds among the various lipid compartments (e.g., adipose tissue, serum lipids, and milk lipids) are correlated Cranmer et al., 2000; USEPA, 2004) . This assumption underlies the hypothesis that as lipids are mobilized from adipose stores during lactation, lipophilic compounds are also mobilized, enter the bloodstream and partition to milk lipids, resulting in excretion of those chemicals from the mother during lactation and decreased adipose stores of the chemicals. Two lines of inquiry that would shed light on whether this hypothesis is supported by the scientific literature are reviewed here: (i) What is known regarding the sources of lipids in human milk and mechanisms of transport of PCDDs/Fs to milk? (ii) For PCDDs/Fs in human milk, what does the research tell us about contributions from lifetime exposures versus exposures during lactation? This second question has been explored by investigating diet and weight change during lactation. Dietary studies have sought to examine whether the daily dietary intake of dioxins is sufficient to account for the mass of dioxins excreted daily via lactation. Weight change (loss) studies during lactation have focused on whether the mother's weight loss during lactation is associated with mobilization of stored dioxins, which might result in increased dioxins in human milk.
What is Known Regarding the Sources of Lipids in Human
Milk and Mechanisms of Transport of Lipophilic Xenobiotics to Milk? There are three main sources of lipids in human milk: (i) fatty acid mobilized from adipose tissue stores (transferred as unesterified fatty acids bound to albumin into mammary alveolar cells (Koletzko et al., 2001) ); (ii) de novo synthesis by the mammary gland and other sites such as the liver; and (iii) dietary lipids (long chain fatty acids absorbed, re-esterified into triacylglycerols, and entering the bloodstream as chylomicrons, transferred to milk (Koletzko et al., 2001) ). Hachey et al. (1987) suggested the following percentages for the relative contributions from these sources, based on their research and the research of others: 59% from tissue synthesis and adipose stores; 10-12% of total milk fat from mammary gland synthesis; 29% of milk fat derived from diet. However, the source of fatty acids is also linked to the dietary state (fasting versus fed); only the fasting state allows for significant transfer of lipids from body stores to alveolar cells (Neville, 2006) . It is likely that the liver makes a contribution to milk lipids as well, but except for cholesterol, which is known to be synthesized in the liver and transferred to the milk, the contribution of liver synthesis/mobilization to milk lipid is unknown.
Although the relative contributions of the three sources of lipids to milk triglyceride have been studied, these data do not provide information on the physiological sources of lipophilic xenobiotics in milk (i.e., diet and/or adipose tissue stores). In fact, ''[a]t present there is little detailed information about the mechanisms and factors regulating entry of drugs and xenobiotic agents into milk'' (McManaman and Neville, 2003) . With dietary exposure to PCDDs/Fs, these compounds are transported principally via chylomicrons in the bloodstream; about 80% of 2,3,7,8-tetrachlorodibenzop-dioxin is associated with the lipoprotein fraction, 15% with protein (serum albumin) and the remainder with cellular components (Henderson and Patterson, 1988) . However, these percentages are affected by the chlorine content of the PCDD/F congener, with higher chlorinated congeners bound in greater percentages to serum proteins other than lipoproteins (Patterson et al., 1989) . Further, ''tissue distribution within the first hour after exposure parallels blood levels and reflects physiological parameters such as blood flow to a given tissue and relative tissue size'' (USEPA, 2004, p. 1-13) . No animal models which examine tissue distribution of PCDDs/Fs after dietary exposure in a lactating animal were located.
PCDDs/Fs in Human Milk: What Does the Research Tell Us About Contributions from Lifetime Exposures Versus
Exposures during Lactation? The principal source of human exposure to PCDDs/Fs is from the diet. Once ingested, the compounds are distributed via the blood to various organs, especially the liver and adipose tissue . The question raised here is: What is known about the relative contributions of diet and adipose stores to PCDDs/Fs in human milk during lactation?
Research on levels of lipophilic compounds in human milk has provided information suggestive of the hypothesis that mobilization of adipose stores and subsequent release of lipophilic compounds from those stores serves as the principal source of those compounds to human milk. For example, many investigators have demonstrated that concentrations of persistent, lipophilic chemicals in human milk decline over the course of lactation (Yakushiji et al., 1978; Yoshida and Nakamura, 1979; Rogan and Gladen, 1985; Klein et al., 1986; Rogan et al., 1986; Fu¨rst et al., 1989; Jo¨dicke et al., 1992; Hori, 1993; Abraham et al., 1994; Schecter et al., 1996 Schecter et al., , 1998 Kang et al., 2003) , and also that levels of these compounds decline with each successive lactation and/or birth (Dillon et al., 1981; Klein et al., 1986; Rogan et al., 1986; Fu¨rst et al., 1989; Mes et al., 1993; Pluim et al., 1993; Vaz et al., 1993; Hong et al., 1994; Newsome et al., 1995; Albers et al., 1996; Kostyniak et al., 1999; Kim et al., 2000; Fitzgerald et al., 2001; Tajimi et al., 2004; Stigum et al., 2005; Uehara et al., 2006) . Taken together, these results are consistent with the hypothesis that lactation serves as a route of elimination, and lipophilic compounds are ''purged'' from the mother's adipose stores. However, not all researchers have shown a decline in levels of lipophilic compounds during lactation (Curley and Kimbrough, 1969; de Bellini et al., 1977; Brilliant et al., 1978; Krauthacker et al., 1980; Mes and Lau, 1983; Mes et al., 1984; Fooken and Butte, 1987; Galetin-Smith et al., 1990; Vaz et al., 1993; Abraham et al., 1994; Kim et al., 2002; Weiss et al., 2003; Suzuki et al., 2005) or with multiple births (Kunisue et al., 2006; Sasamoto et al., 2006) and recent data suggest that the picture is more complex than previously hypothesized.
For example, Sjo¨din et al. (2005) designed a study specifically to quantify rates of elimination of several lipophilic compounds over the duration of lactation. However, no declines (and slight increases in some cases) in lipidadjusted levels of PDBEs 47 and 99, hexachlorobenzene (HCB), 2,2-bis(4-chlorophenyl)-1,1,1-trichloroethane (p,p'-DDT) and polychlorinated biphenyls (PCBs 118 and 153) over 120 days postpartum for three mothers were observed (Figure 3 ). Jin and Su (2005) reported an overall decline in average TEQs (lipid basis) over the first 30 days of lactation, but certain congeners increased in concentration over that same time period. In addition, in some individuals, levels have not declined with each successive lactation ) (although Nakano et al. (2005) did not state whether multiparas in their study had breastfed previous children). In an earlier review of the factors influencing levels of organochlorine (OC) pesticides in human milk, Harris et al. (2001) concluded that although importance of mobilization of fat reserves was commonly cited by investigators, ''little evidence was presented to support this.'' Conflicting information has also been published regarding the importance of adipose stores versus diet as contributors to levels of PCDDs/Fs in human milk. These studies generally fall under two categories: (i) studies that measure PCDDs/Fs and other lipophilic compounds in the lactating mother's adipose tissue, serum, and/or milk, and (ii) studies that focus on the effects of weight change and/or diet during lactation. The results of research focused on sources of lipophilic compounds in general, and PCDDs/Fs in particular, to human milk during lactation are briefly discussed here.
Research on Levels of Lipophilic Compounds in Human Tissues and Fluids during Lactation Several investigators
have measured PCDDs/Fs and other lipophilic compounds in the lactating mother's adipose tissue, serum, and/or milk with the goal of shedding light on the sources of these compounds in human milk. The ideal study design would include measurements of PCDDs/Fs in adipose, serum, and human milk lipids, with sampling of these matrices occurring at multiple time points on the same day and over the course of lactation. In addition, the study design would carefully document the history of the mother's breastfeeding behavior over the course of lactation. However, for practical reasons, this type of study has not been conducted, as adipose samples are typically collected during Caesarean sections, with serum and milk sampling occurring at other times. Although numerous studies have reported on partitioning of lipophilic compounds among lipid compartments in breastfeeding women, we focus here on those studies that sought to connect this information with sources of those compounds for human milk. Miyata et al. (2001) collected milk from nine mothers in Japan up to 180 days postpartum and measured levels of PCDDs/Fs in those samples. They hypothesized that if the PCDDs/Fs in human milk lipids were derived from stores in adipose tissue, then levels in milk should decline in a linear manner postpartum. However, PCDDs/Fs in the milk samples did not decline consistently. Average concentrations on a lipid basis decreased from day 5 postpartum to day 30 (23.0 pg TEQ/g lipid to 19.1 pg TEQ/g lipid). Over a longer time period (from 30 to 180 days postpartum), levels of PCDDs/Fs in another group of women declined from 14.5 to 12.2 pg TEQ/g lipid. These average values mask the individual results, which Miyata et al. note are not consistent across participants: some mothers showed a decline in levels, whereas others showed an increase postpartum. In addition, the rate of decline during the period 30-90 days postpartum was one seventh the rate of decline during 5-30 days postpartum. From 90 to 180 days postpartum, the rate of decline was one fifteenth the rate of decline during days 5-30 postpartum. Because the decline was not linear, Miyata et al. concluded that other sources besides stored adipose lipids are important, and proposed diet as the main source of PCDDs/ Fs in human milk. It is not clear that mobilization from adipose stores should necessarily result in a linear decline in lipid-adjusted concentrations of PCDDs/Fs in milk as the physiological processes responsible for transport of PCDDs/ Fs to milk are not yet fully described.
Although earlier research suggested that lipid-adjusted levels of dioxins, furans, and PCBs were roughly equivalent in serum and milk (reviewed by Aylward et al., 2003) , a more recent study demonstrated that certain lipophilic compounds preferentially partition into lipids of certain matrices over others. Wittsiepe et al. (2004) measured levels of PCDDs/Fs and PCBs in human milk and blood from 169 participants. The majority of the blood samples were obtained in the 32nd week of pregnancy, with some collected postpartum. Milk was to be obtained at the second week postpartum, but in many cases was collected at a later date. Thus, the study does not give information on milk and blood partitioning with simultaneous collection. Wittsiepe et al. (2004) observed that higher chlorinated congeners were found in blood lipids in higher concentrations than in milk lipids. Lower chlorinated congeners such as pentachlorinated biphenyls were found in milk lipids at 1.5 times the level in the mother's blood lipid. Congener-specific differences between milk and blood lipids were also shown by Nakano et al. (2005) , with levels of several of the congeners at higher concentrations in blood as compared to milk. These data are difficult to interpret in the context of lipid mobilization as blood samples were taken possibly before lipid mobilization during lactation. However, the studies highlight the fact that several factors may influence congener-based differences, including differences in lipophilicity and molecule diameter and weight, which may be tied to membrane permeability (Wittsiepe et al., 2004) . These factors likely play an important role in the transfer of chemicals into mammary cells, regardless of the origin of the compounds. Harden et al. (2004) observed that a ''[s]hift in congener profile from the blood to breast milk is indicative of a kinetic limitation related to the physico-chemical properties of the individual congeners.'' PCDDs/Fs and co-PCBs were measured in maternal blood, cord blood, placenta, milk, and adipose tissue of 22 mothers in Japan . Concentrations of lipid-adjusted PCDD/F TEQs were not significantly different in milk sampled after 1-month postpartum as compared to milk collected 310 days postpartum. Suzuki et al. (2005) suggested that the source of PCDDs/Fs in milk is not only adipose tissue, but ''other factors.'' Certain fatty acids in food form chylomicrons upon entering the intestines, and after absorption, enter the lymph and are transferred to the mammary glands via blood; Suzuki et al. (2005) hypothesize that PCDDs/Fs in food are transported to the mammary glands by the same mechanism. Waliszewski et al. (2001) measured levels of several OC pesticides in maternal adipose tissue, serum, colostrum and mature milk, and cord blood (n ¼ 60). Samples were collected as follows: blood 2 days before delivery, cord blood and adipose tissue during surgery, colostrum 5 days postpartum, and mature milk 30 days postpartum. Levels of total hexachlorocyclohexane (HCH) isomers in adipose tissue, colostrum, and mature milk (mean7SD) were 0.1670.12, 0.1070.07, and 0.0670.05 mg/kg lipid, respectively. They ascribe the difference in observed levels of HCH in colostrum and milk to the different chemical compositions of colostrum and mature milk. They report that the former contains higher levels of lipoproteins, which bind readily to OC pesticides and result in higher concentrations in the colostrum. However, the HCH concentrations reported for colostrums and mature milk do not appear to be statistically significantly different. The authors also note that the adipose tissue absorbs OC pesticides more readily, yielding even higher concentrations of these compounds. However, these differences were not uniformly observed, as levels of DDT compounds in colostrum and adipose tissue were 5.71 and 5.66 mg/kg lipid, respectively, again suggesting that more complex processes are involved in transport of these classes of compounds.
Research on Effects of Weight Loss and Change in Diet during Lactation In the absence of longitudinal studies, which include sampling and analysis of adipose tissue, serum, and milk, the most valuable types of studies for ascertaining the relative contributions of PCDDs/Fs to milk of adipose tissue and current diet involve examination of weight loss during lactation and changes in diet during lactation. Research on these two subjects is described here.
According to Lovelady et al. (1999) , a lactating woman who loses a large amount of body fat would experience an increase in the concentration of lipophilic persistent compounds in her remaining adipose tissue, and thus experience an increase (or less of a decrease) in levels of those compounds in her blood and milk (i.e., the presumed decrease in levels of those compounds in milk over the course of lactation would be offset by the increased concentrations of those chemicals in the remaining adipose tissue). Alternatively, if adipose stores were the predominant source of lipophilic persistent compounds to human milk, then one might expect that weight loss during lactation would result in mobilization of lipids and a subsequent increase in levels of those compounds to milk. Thus, two potentially competing processes may be affecting milk concentrations of these compounds. A further complication is that mobilization of adipose stores may also result in increased biliary and non-biliary transport of stored lipophilic compounds to the intestines resulting in increased fecal excretion of those compounds (Jandacek and Tso, 2001) .
Investigations into the effect of weight loss during lactation have yielded mostly negative results (i.e., no effect on concentrations of persistent lipophilic compounds in human milk) (LaKind et al., 2004) . However, there are very few studies from which to draw general conclusions (Table 3) . Vaz et al. (1993) observed increases in levels of lipophilic persistent compounds in the milk of a woman who fasted during lactation (losing 10 kg). However, Lovelady et al. (1999) found that moderate weight loss (average weight loss of 4.1 kg) did not result in increased levels of lipophilic compounds in the milk of mothers. Similarly, in a study of 165 women living in Finland, there was no relationship between lipophilic compounds in human milk and weight loss (Mussalo-Rauhamaa et al., 1988) .
One non-human mammalian study found changes in concentrations of OC compounds in the milk of fasting polar bears (Polischuk et al., 1995) . Polischuk et al. (1995) observed that as fasting progressed and adipose tissue amounts declined, the concentrations of OCs (PCBs, chlorobenzenes, and chlordanes) in the adipose tissue lipids and milk lipids increased (these results were not observed for DDT or HCH). This clearly represents an extreme situation, as before fasting, polar bear adipose tissue may be as high as 50% of the body mass, and the fasting period can be extremely lengthy (around 1 year and covering the time period of gestation and lactation) after which adipose tissue may be as low as 10% of body mass (Polischuk et al., 1995) . In addition, human and polar bear accumulation of these compounds may differ. Thus, the applicability of these results to humans is uncertain.
Two studies were identified in which the effects of diet change during lactation on levels of PCDDs/Fs in human milk were specifically studied. Pluim et al. (1994) introduced two different diets to 34 breastfeeding women to determine the effect on levels of PCDDs/Fs in milk. The diets were a low fat/ high carbohydrate/low dioxin diet and a high fat/low carbohydrate/low dioxin diet and were followed for 5 days during the fourth week postpartum. Milk was sampled before and after the diet change, and PCDDs/Fs and fatty acid concentrations were determined. Fatty acid profiles were significantly altered by the diets. However, short-term changes in diet during lactation did not appear to influence the levels of PCDDs/Fs in the milk. PCDDs/Fs in the participants' diets were not measured, but were estimated based on representative levels in foodstuffs in the Netherlands.
Human milk samples (30 samples over 5 days) and samples of diet (over 3 days) were obtained from one mother whereas for two additional mothers, human milk samples were collected over 5 days including days 3, 4, and 5 during which the two mothers fasted (Miyata et al., 2006) . Levels of dioxin TEQs in the first mother's diet fluctuated substantially over the 3 days, as did levels in her milk. For the two mothers who fasted, dioxins in human milk decreased substantially during fasting. Miyata et al. (2006) concluded that the dioxins in human milk are influenced by both long-term accumulation in the body but also with current dietary intake.
Discussion
Recognizing the caveats associated with comparison of biomonitoring studies conducted over time with varying protocols, numbers of milk donors, and other factors that create uncertainty in interstudy comparison, international human milk biomonitoring data suggests that the global decline in levels of PCDD/F TEQs in human milk has continued into this century.
Whether a woman's PCDD/F lipid levels can be reduced by lactation is less clear. The conventional wisdom explaining the presence of PCDDs/Fs in human milk and the changes in concentrations of those chemicals in milk during lactation is that a lifetime accumulation of PCDDs/Fs from dietary exposures results in a legacy accumulation of PCDDs/Fs in adipose tissue. During lactation, adipose tissue stores are mobilized and lipids and lipophilic compounds (including PCDDs/Fs) enter the bloodstream and milk. Thus, one would expect the following associations: (i) increased age at first lactation and higher levels of those chemicals in milk, owing to greater lifetime exposure and accumulation in adipose stores; (ii) increased total duration of lactation with lower levels in milk, owing to elimination of stored chemicals from adipose tissues via breastfeeding; and (iii) increased levels of chemicals in milk with weight loss during lactation owing to mobilization of adipose tissue and/or increased concentrations of chemicals in remaining adipose tissue.
A positive relationship between levels of persistent lipophilic compounds in milk and the mother's age has not been uniformly reported (Harris et al., 2001 ; Sudaryanto (Jensen and Slorach, 1991; LaKind et al., 2004) . At present, it is unclear whether body mass index (BMI) also influences this relationship; one investigation found a negative association between BMI and TEQ levels in human milk (Houweling et al., 2002) , whereas others have reported no association between BMI and TEQs in milk (Nakamura et al., 2000; Lignell et al., 2005) . In addition, whereas increasing concentrations of many of these chemicals with age may be due to greater lifetime accumulation, it may also be due to the fact that older women had exposures at a time when these chemicals were not yet banned or restricted, or during a time after bans/restrictions but when environmental levels were higher. Similarly, not all studies have observed declines in chemical concentrations in human milk with increasing parity (Harris et al., 2001) , nor have results regarding changes in chemical concentration over the course of one lactation been consistent (it has been hypothesized that the rate of elimination may be influenced by such factors as the number of previous children breastfed, the initial level of the chemical in the mother's lipids, diet, percent lipid in human milk, and the volume of milk consumed by the infant (LaKind et al., 2001) ). Finally, there are simply too few studies on the effects of weight loss and/or diet change during lactation to draw any firm conclusions regarding mechanisms for introducing PCDDs/ Fs into milk.
One approach to assessing the plausibility of substantial dietary contributions during lactation to PCDD/F levels in human milk is to compare estimates of daily intake of these compounds with daily excretion owing to lactation. Estimates of intake require information on levels of PCDDs/Fs in the diet combined with information on food intake. Thus, in the absence of studies on individual diet during lactation, intake estimates are, by necessity, based on larger population studies. Similarly, estimates of daily TEQ excretion owing to lactation are arrived at by combining information on levels of PCDDs/Fs in human milk with an estimate of the volume of milk consumed by the infant. For intake, a range of values has been given, with for example, total dietary intake of PCDDs/Fs for the general population in Catalonia, Spain reported to be 95.4 pg WHO-TEQ/day (Llobet et al., 2003) and for the US, 38 pg WHO-TEQ/day (USEPA, 2004) . For excretion, Miyata et al. (2001) estimated average infant daily intake of PCDDs/Fs (and thus excretion owing to lactation) to be approximately constant (based on milk data from nine women) ranging from 318 to 509 pg TEQ/day, during days 5-180 postpartum. Lower infant intakes were estimated by Chao et al. (2005) (approximately 84 pg TEQ/day) and Schuhmacher et al. (1999) (217 I-TEQ/day). These latter values are closer to daily intake estimates of PCDDs/Fs from diet, and could plausibly support the hypothesis that diet during lactation contributes a sufficient daily dose of the PCDDs/Fs to human milk during lactation to account for a substantial portion of these chemicals excreted via breastfeeding. Schuhmacher et al. (2004a, b) described parallel declines in intake of PCDDs/Fs in diet over a 3-year study period in Catalonia, Spain (210-60 pg I-TEQ/day, a 70% reduction) and levels in plasma (27.0-15.7 pg I-TEQ/g lipid, a 41% reduction), milk (11.8-10.0 pg I-TEQ/g lipid, a 15% reduction), and adipose tissue (30.99-9.22 pg I-TEQ/g lipid, a 70% reduction) in the study populations. Because the study design included two sets of study participants and dietary information for the individuals was not collected, it is unclear whether these changes in human levels are related to the participants' current diet or whether the declines follow the overall global decline. Nevertheless, the percent decline in adipose tissue levels over the 3-year period is striking, as it approximates the percent decline in dietary intake.
However, the question of whether the presence of PCDDs/ Fs in milk is from the lifetime accumulation of PCDDs/Fs in adipose tissue or current diet (or, as is more likely, a complex combination of both) remains unanswered (Figure 4) . It has been assumed though, that because the main contributor of PCDDs/Fs to milk during lactation is stored chemicals in adipose tissue, there are no actions a breastfeeding mother can take to reduce her milk levels. In addition, the study by Pluim et al. suggests that short-term changes in diet designed to reduce mobilization of lipid stores do not result in reductions in PCDDs/Fs in human milk. Research is needed to determine whether human milk PCDD/F concentrations increase with fasting (which would conflict with the findings of Miyata et al., 2006) , a behavior that results in mobilization of fatty acids from the adipose tissue in greater quantity, or after a lipid-rich meal when there would be greater concentration of circulating triglycerides which might be involved in the transport of PCDDs/Fs. Alternatively, Figure 4 . Research has provided information on sources of lipids in milk, with limited data given on relative percents from these sources (Hachey et al., 1987) . The relative contributions of current dietary exposure and historical exposures (as represented by levels in adipose tissues) to PCDDs/Fs in milk has not been described. (Rembrandt, Seated Naked Woman, 1658, courtesy of Windsor Fine Art, New Orleans. www.windsorfineart.com).
there may always be a certain amount (depending on overall levels of PCDDs/Fs in the body) bound to albumin in the plasma. In this case, PCDDs/Fs would simply be delivered to the milk along with other molecules brought into the mammary gland by albumin.
Many studies have explored the influence of diet on levels of lipophilic chemicals in milk, but most have relied on questionnaire data which, unless designed specifically for this purpose, do not allow for the differentiation between past diet and diet during lactation. A longitudinal diet/biomonitoring study that captures changes in intake of PCDD/Fs during lactation while measuring levels of PCDDs/Fs in the mother's adipose tissue, serum and milk is complex but technically feasible, and would provide critical information on the physiological origins of PCDDs/Fs in breast milk.
Conclusions
Only a few studies have specifically sought to identify sources of PCDDs/Fs (or other persistent lipophilic compounds) in human milk both immediately postpartum and over the duration of lactation. For PCDDs/Fs, variations across congeners in rates of metabolism and excretion, lipophilicity, molecule size, and other factors make it difficult to determine sources of these chemicals in milk. Some of these factors will likely be masked by presenting information as TEQs, rather than considering congener-specific information.
In the past three decades, we have witnessed a substantial decline in levels of PCDDs/Fs in the environment and in humans, including in human milk. Data from the past several years suggest that this decline continues. Whether diet during lactation has a greater influence on milk levels of PCDDs/Fs than previously suspected, and whether infant exposures to PCDDs/Fs from breastfeeding could be reduced by changes in diet during lactation, are important F and currently unexplored F lines of inquiry.
